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thrombosis with bolus dose TenecteplaseFig. 1 e Doppler showing high aortic valve gradient before
thrombolysis.Prosthetic valve thrombosis (PVT) defined as any obstruc-
tion of prosthesis by noninfective thrombotic material remains
a serious and potentially lethal complication. Treatment of PVT
includes administration of thrombolytic agents or surgery.
Various thrombolytic treatments including streptokinase, uro-
kinase and recombinant tissue plasminogen activators have
been reportedwith variable success rates. However, the data on
the use of Tenecteplase (a synthetic tissue plasminogen acti-
vator) is limited. We report here a case of 28-year-old male
patient, who presented to us with Aortic PVT of 4 weeks
duration and successfully treated with i.v bolus Tenecteplase.
The patient underwent aortic valve replacement with St.
Jude 21 mm mechanical prosthetic valve on 15/2/2007 for se-
vere aortic regurgitation and was on oral anticoagulant
(warfarin 5 mg and 7.5 mg on alternate days), maintaining INR
in therapeutic range during regular follow up over the last 5
years. He presented on 19/6/2012 with progressively increasing
dyspnea of NYHAclass II of 1month duration. Itwas found that
his oral anticoagulant was changed from Warfarin to Acitrom
(Nicoumalone) 2 mg daily by another physician inspite of
therapeutic INR. Followup INRmeasurements are not available
after the changeover. Further he stopped oral anticoagulant for
1 week before presentation. On examination he was comfort-
able at rest, vitals normal, not in heart failure and auscultation
revealed decreased intensity of prosthetic valve click and a
grade 3/6 midsystolic murmur. 2DECHO revealed decreased
mobility of aortic prosthetic leaflet, Aortic maximum velocity
was 5.3 m/second,maximumandmean gradients across aortic
valve was 113 mmHg and 66 mmHg (Fig. 1). His LVEF was 64%.
Fluoroscopy and TEE showed severely restricted aortic leaflet
mobility. His INR was 1.38.
After discussing various options, we chose to treat himwith
intravenous Tenecteplase (Metalyse, Boehringer Ingelheim)
40 mg bolus as in acute myocardial infarction regimen, fol-
lowed by enoxaparin and warfarin. Post thrombolysis, patient
subjectively felt improvement within 6 hours, prosthetic valve
clicks became sharp,midsystolicmurmur decreased to grade 1/
6. After 48 hours vitals were stable, click was well audible and
murmur disappeared. 2DECHO showed full mobility of aortic
leaflets, and aortic valve maximum and mean gradients were
decreased to 16 mmHg and 9 mmHg (Fig. 2). Fluoroscopy and
TEE demonstrated completely mobile prosthetic aortic leaflets.
Patient was discharged home on therapeutic INR of 3.2.PVT has an estimated incidence of 0.03%e4.3% per year1 and
isreported tooccur in0.5%e8%of the left-sidedprostheticvalves
and in up to 20% of tricuspid prostheses. The most common
causeofPVT is inadequateanticoagulant therapy (inupto82%of
cases). Optimal management of PVT remains controversial. As
per ACC/AHA Guidelines 2008, for left-sided PVT, emergency
surgery is indicated in patients with NYHA functional class III-
eIV (class IIa) and fibrinolytic therapy for patients in functional
class IeII (class IIb).2 Lengyel and coworkers consider throm-
bolysis as the first line treatment for obstructive PVT, indepen-
dent of NYHA class and thrombus size, if there are no
contraindications.3 On the other hand, in a recent series of 210
patients reportedbyRoudaut, surgical treatmentwasassociated
with significantlybetter long-termresults in termsof recurrence
and mortality and a lower incidence of embolic complications,
which reached 15% in the fibrinolysis group.4
The fibrinolytic agents used for treatment of PVT are strep-
tokinase, urokinase and recombinant tissue plasminogen acti-
vator (alteplase). The newer fibrinolytic agent Tenecteplase is a
synthetically engineered variant of alteplase designed to have
increasedfibrinspecificity,greaterefficacy, increasedresistance
to plasminogen activator inhibitor-1 (PAI-1) and a longer half-
life, ease of administration as a single intravenous bolus dose.
Fig. 2 e Doppler showing normal aortic valve gradient after successful thrombolysis.
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there are anecdotal reports of its use in treatment ofmitral and
Aortic PVT. Charokopos et al were the first to publish report of
Tenecteplase for Aortic PVT; the patient was defaulted on oral
anticoagulants and presented with PVT on reinitiating oral an-
ticoagulants without heparin cover.5 Our patient was symp-
tomatic since 3 weeks; the thrombusmight have started slowly
progressing, impinging valve mobility. As Tenecteplase ismore
fibrin specific and easy to administer, we thought it as better
choice insucha longerduration thrombus. Incase thrombolysis
fails, re-exploration and possible Aortic valve replacement was
planned.RecentlySharmaetal6published their experienceof 10
patients with left-sided PVT which included one patient with
both Mitral and Aortic PVT and one patient with Aortic PVT.
PVT may be successfully treated with Tenecteplase. More
experience of its use might establish its role as thrombolytic
agent of choice in management of PVT. Proper care should be
exercised when switching from one oral anticoagulant to
another.r e f e r e n c e s
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